Results 161 to 170 of about 4,314 (231)

Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.

Health Technol Assess
Edwards SJ, Farrar BG, Ennis K, Downes N, Wakefield V, Mackenzie I, Walters A, Jhita T.   +7 more
europepmc   +1 more source

Optimizing Flumatinib Therapy in Chinese Chronic-Phase Chronic Myeloid Leukemia Based on Therapeutic Drug Monitoring. [PDF]

Drug Des Devel Ther
Cheng F, Wang F, Cui Z, Li Q, Liu X, Li W.   +5 more
europepmc   +1 more source

Spirocyclohexane-Chroman-4-one Derivatives as Selectively Cytotoxic Agents in Breast Cancer Models. [PDF]

ACS Med Chem Lett
Ipatova DA, Ikonnikova VA, Kungurtsev KD, Kashapov AI, Shafikov RR, Kartsev VG, Glushkov AK, Myasnyanko IN, Baranov MS, Mikhaylov AA, Dontsova OA, Skvortsov DA.   +11 more
europepmc   +1 more source

The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study. [PDF]

Sci Rep
Oruç A, Deliktaş Onur İ, Uyar GC, Şahin TK, Tünbekici S, Arslan Kapuci A, Ulukal Karancı E, Kemik F, Yıldırım Dişli Ş, Ateş Ö, İnanç İmamoğlu G, Aksoy S, Çakar B, Özdemir N, Öztürk B, Selçukbiricik F, Koçak MZ, Karakurt Eryılmaz M, Araz M, Artaç M.   +19 more
europepmc   +1 more source

Lorlatinib and Amivantamab: A Paradigm Shift in <i>EGFR</i> and <i>ALK</i> Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making. [PDF]

Oncol Res
Maione P, Palma V, Gridelli C.
europepmc   +1 more source

Recent advances in magnetic nanocatalysts for synthesis of imidazo[1,2-<i>a</i>]pyridine frameworks. [PDF]

RSC Adv
Shuheil MA, Priya GP, Ali AM, Sasikumar Y, Aldulaimi A, Sharma R, Singh A, Ali R, Kazemi M.   +8 more
europepmc   +1 more source

Indolylmaleimide derivatives as a new class of anti-leishmanial agents: synthesis and biological evaluation. [PDF]

RSC Med Chem
Das S, Babu NK, Mazire P, Roy A, Kumar R, Singh S, Sharma DK.   +6 more
europepmc   +1 more source

Emergence of PALB2 Reversion Mutations as a Mechanism of Resistance to Niraparib in Breast Cancer: A Case Report. [PDF]

Cancer Sci
Kawamura M, Tada H, Shirota H, Dobashi M, Takenaga N, Yasojima H, Harada-Shoji N, Komine K, Nakamura K, Miyashita M, Kawakami H.   +10 more
europepmc   +1 more source

First- Versus Second- or Subsequent-Line Use of Cyclin-Dependent Kinase 4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic or Recurrent Breast Cancer: A Multicenter, Retrospective Cohort Study. [PDF]

Medicina (Kaunas)
Yao S, Imoto S, Tsuchiya A, Isaka H, Seki H, Asaga S, Yokoi S, Koneri K, Maeda H, Goi T.   +9 more
europepmc   +1 more source

Nucleophilic Additions of Organolithium Reagents to Heterocyclic Aldimines. [PDF]

Synlett
Baek J, Hoisington WA, Galgano ES, Schneider EH, Barker TJ.   +4 more
europepmc   +1 more source